Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 8:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 57 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Cephalexin Clear all
Completed Not applicable Interventional

Endourology Disease Group Excellence (EDGE) Consortium: Antibiotics (Abx) for Percutaneous Nephrolithotomy (PCNL) Part 2

NCT02829060
View directory record Official record
Conditions
Nephrolithiasis, Urinary Tract Infection (UTI), Sepsis
Interventions
Nitrofurantoin 100 MG, 7d, Gentamicin, 5mg/kg, Ampicillin 2g, Nitrofurantoin 100 mg, 48 hrs, Gentamicin, 80 mg, 7d, Gentamicin, 80 mg, 48hr
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
Not listed
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Sep 1, 2026, 8:23 PM EDT
Not listed Phase 4 Interventional

Struvite Stones Antibiotic Study

NCT02375295
View directory record Official record
Conditions
Kidney Stones
Interventions
ciprofloxacin, cotrimoxazole-trimethoprim, macrodantin
Drug
Lead sponsor
University of British Columbia
Other
Eligibility
19 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
11
States / cities
Scottsdale, Arizona • San Diego, California • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated May 16, 2022 · Synced Sep 1, 2026, 8:23 PM EDT
Completed Phase 4 Interventional Results available

Randomized Trial of Culture Directed Versus Empiric Antibiotics for Urinary Tract Infections in Older Women

NCT05726318
View directory record Official record
Conditions
UTI
Interventions
Antibiotics
Drug
Lead sponsor
Megan Bradley
Other
Eligibility
65 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Sep 1, 2026, 8:23 PM EDT
Completed Not applicable Interventional Results available

Study of New Antibiotic Regimen for the Treatment of Uncomplicated Cellulitis in Emergency Department Patients

NCT00676130
View directory record Official record
Conditions
Cellulitis
Interventions
trimethoprim-sulfamethoxazole, Cephalexin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
12 Months and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2012 · Synced Sep 1, 2026, 8:23 PM EDT
Recruiting Phase 4 Interventional

Extended Oral Antibiotic Prophylaxis in Diabetic Fracture Patients

NCT07561541
View directory record Official record
Conditions
Fracture Lower Leg, Diabetes, Fracture Fixation, Internal
Interventions
Cefadroxil 500 mg Capsules, Clindamycin, Bactrim DS
Drug
Lead sponsor
Texas Tech University Health Sciences Center, El Paso
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Los Angeles, California • El Paso, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 1, 2026, 8:23 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Strategies Using Off-Patent Antibiotics for Methicillin Resistant S. Aureus "STOP MRSA"

NCT00729937
View directory record Official record
Conditions
Staphylococcal Infection
Interventions
Cephalexin, Clindamycin, Placebo, Trimethoprim-sulfamethoxazole
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
2,265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
5
States / cities
Phoenix, Arizona • Sylmar, California • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2015 · Synced Sep 1, 2026, 8:23 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Treatment of Asymptomatic Bacteriuria in Pregnancy

NCT02911662
View directory record Official record
Conditions
Bacteriuria (Asymptomatic) in Pregnancy
Interventions
Cephalexin, Nitrofurantoin
Drug
Lead sponsor
Trinity Health Michigan
Other
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Ypsilanti, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Sep 1, 2026, 8:23 PM EDT
Completed Phase 1 Interventional

Oral Amoxicillin and Cephalexin PK/PD in Neonates

NCT04916951
View directory record Official record
Conditions
Neonatal Infection
Interventions
Amoxicillin, Cephalexin
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
1 Day to 60 Days
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 1, 2026, 8:23 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Postoperative Antibiotic Requirements Following Immediate Breast Reconstruction

NCT01244698
View directory record Official record
Conditions
Bacterial Infection, Anti-infective Agents, Breast Implantation
Interventions
Cefadroxil discontinued early, Cefadroxil until drain removal
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older · Female only
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2014 · Synced Sep 1, 2026, 8:23 PM EDT
Enrolling by invitation Phase 4 Interventional

Antibiotic Prophylaxis in High-Risk Arthroplasty Patients

NCT04297592
View directory record Official record
Conditions
Infections Joint Prosthetic, Overweight or Obesity, MSSA Colonization, MRSA, Chronic Kidney Diseases, Diabetes, Autoimmune Diseases, Inflammatory Disease, Tobacco Use
Interventions
Cephalexin, Doxycycline, Cefadroxil
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 99 Years
Enrollment
4,618 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
2
States / cities
Iowa City, Iowa • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 1, 2026, 8:23 PM EDT
Recruiting Phase 4 Interventional

Prophylactic Antibiotics for Outpatient Urethral Bulking

NCT07501065
View directory record Official record
Conditions
Urinary Tract Infections, Stress Urinary Incontinence, Urinary Incontinence
Interventions
Bactrim (800/160 mg), Keflex (500 mg), Cipro (250 mg), or Macrobid (100mg)
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 1, 2026, 8:23 PM EDT
Enrolling by invitation Phase 3 Interventional

Antibiotic Prophylaxis in Rhinoplasty

NCT04194216
View directory record Official record
Conditions
Nasal Obstruction, Nasal Surgical Procedures
Interventions
Intra-operative single intravenous(iv) dose of "cephalexin" 2 g or "clindamycin" 900 mg., Intra-operative single dose (iv) of "cephalexin" 2 g or "clindamycin" 900 mg and postoperative oral dose of "cephalexin" 250mg (every 4 hours) or "clindamycin" 150mg(every 6 hours) for 3 days
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
864 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 1, 2026, 8:23 PM EDT
Recruiting Not applicable Interventional

Nailbed Repair for Patients With Nailbed Injuries

NCT07388823
View directory record Official record
Conditions
Nail Bed Injury, Nail Laceration, Nail Plate Disruption
Interventions
Nail Bed Repair, Nail bed dressing
Other
Lead sponsor
Stanford University
Other
Eligibility
2 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 1, 2026, 8:23 PM EDT
Completed Phase 3 Interventional Results available

Perioperative Antibiotic Therapy to Prevent Cardiac Implantable Electronic Device Infections.

NCT02809131
View directory record Official record
Conditions
Sick Sinus Syndrome, Complete Heart Block, Syncope, Chronic Systolic Heart Failure
Interventions
polymixin/bacitracin, cephalexin, or levofloxacin, or clindamycin, Saline
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
1,010 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 8, 2022 · Synced Sep 1, 2026, 8:23 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT02014558
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Gilteritinib, Voriconazole, Midazolam, Cephalexin
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
23
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Sep 1, 2026, 8:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Cefadroxil 500 mg Capsules Under Fasting Conditions

NCT00834275
View directory record Official record
Conditions
Healthy
Interventions
Cefadroxil 500 mg Capsules, DURICEF® capsules 500 mg
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2024 · Synced Sep 1, 2026, 8:23 PM EDT
Withdrawn Phase 4 Interventional

Role of Prophylactic Postoperative Antibiotics in HoLEP

NCT05274672
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Urinary Tract Infections
Interventions
Nitrofurantoin, Cephalexin, Sulfamethoxazole Trimethoprim Combination, Ciprofloxacin, Holmium Laser Enucleation of prostate
Drug · Procedure
Lead sponsor
Baylor Research Institute
Other
Eligibility
40 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Temple, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 1, 2026, 8:23 PM EDT
Completed Phase 2 Interventional Results available

The SCOUT Study: "Short Course Therapy for Urinary Tract Infections in Children"

NCT01595529
View directory record Official record
Conditions
Urinary Tract Infection
Interventions
Cefixime, Cephalexin, Placebo, Trimethoprim/Sulfamethoxazole
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Months to 10 Years
Enrollment
717 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Sep 1, 2026, 8:23 PM EDT
Terminated Phase 3 Interventional

S9809, Ciprofloxacin Compared With Cephalexin in Treating Patients With Bladder Cancer

NCT00003824
View directory record Official record
Conditions
Bladder Cancer
Interventions
cephalexin, surgical procedure, Ciprofloxacin
Drug · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
90
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2012 · Synced Sep 1, 2026, 8:23 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Single Dose Aminoglycosides for Acute Uncomplicated Cystitis in the Emergency Department Setting

NCT05702762
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
Gentamicin, Standard of Care
Drug
Lead sponsor
Mercy Health Ohio
Other
Eligibility
18 Years and older · Female only
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Youngstown, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Sep 1, 2026, 8:23 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Prophylactic Antibiotic Administration for Bladder OnabotulinumtoxinA Injection

NCT05719285
View directory record Official record
Conditions
Overactive Bladder, Overactive Bladder Syndrome, Urge Incontinence, Urinary Incontinence, Urge
Interventions
Single-Dose Antibiotic, Multi-Dose Antibiotic
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 1, 2024 · Synced Sep 1, 2026, 8:23 PM EDT
Completed Phase 3 Interventional Results available

Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA

NCT02814916
View directory record Official record
Conditions
Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections, Staphylococcal Skin Infections
Interventions
Dalbavancin, Vancomycin, Oxacillin, Flucloxacillin, Cefadroxil, Clindamycin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
0 Years to 17 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
15
States / cities
Mobile, Alabama • Phoenix, Arizona • La Palma, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 1, 2026, 8:23 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

NCT04278404
View directory record Official record
Conditions
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Interventions
The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Duke University
Other
Eligibility
0 Years to 20 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
49
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 1, 2026, 8:23 PM EDT
Withdrawn Not applicable Interventional

Effect of Topical and Systemic Decolonization of Staphylococcus Aureus (SA) in Pediatric Cystic Fibrosis (CF) Patients

NCT01229553
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
decolonization
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
2 Months to 23 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jun 10, 2015 · Synced Sep 1, 2026, 8:23 PM EDT